CannabisNewsBreaks

MondayJul 02, 2018 11:55 am

CBDNewsBreaks – Pivot Pharmaceuticals Inc.’s (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) RTIC Powder Opens Doors for Supply Contracts

Pivot Pharmaceuticals’ (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) patented Ready To Infuse Cannabis (“RTIC”) powder is drawing the attention of respected cannabis brands in California, resulting in potential manufacturing and supply agreements for the company. An article further discussing the company reads: “Pivot’s RTIC process and Solmic Micelle water-soluble technologies will be used to generate a dry cannabis powder that can be used as a baking additive, in pet products and in a variety of retail items. Part of the manufacturing facility will be used to produce topical creams and oral drug delivery technologies, but, at the moment, one of…

Continue Reading

MondayJul 02, 2018 9:30 am

CBDNewsBreaks – EVIO, Inc. (EVIO) Files Preliminary Non-Offering Prospectus with the Ontario Securities Commission

EVIO, Inc. (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry, this morning announced that it has filed and obtained a receipt for its preliminary non-offering prospectus with the Ontario Securities Commission. Notably, this filing is required for EVIO to qualify in becoming a reporting issuer in Ontario, Canada. After the Ontario Securities Commission has completed its review and provided comments on the preliminary prospectus, EVIO is expected to proceed with filing its non-offering (final) prospectus with the commission. Per the update, when the company receives final receipt for this filing, it intends…

Continue Reading

MondayJul 02, 2018 9:24 am

CBDNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF) Names New CEO, Interim CFO

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTC: TGODF) this morning announced the resignation of CEO, Co-Chairman & Director, Robert Anderson, effective immediately, due to health concerns. The board has appointed the company’s current CFO, Brian Athaide, as CEO to ensure a well-ordered transition and continued execution of the company’s business strategy. The board appointed VP of Finance, Julia Golubovskaya, as interim CFO. Jeff Scott, presently actitng as Co-Chair, will undertake the role of Chairman of the Board. “I feel privileged to take on this new role as CEO and ensure the company delivers on…

Continue Reading

FridayJun 29, 2018 12:40 pm

CBDNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Closes Oversubscribed Private Placement

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the closing of its oversubscribed non-brokered private placement financing, which was previously detailed on April 9, 2018. Per the update, a total of 130,779,750 units were issued under the financing at a price of $0.05 per unit for total gross proceeds of more than $6.5 million. “I am very pleased to announce this oversubscribed placement due to investor demand in our financing and see this as a strong endorsement of the quality of our research programs and management team,” Stephen Van Deventer, chairman, CEO and…

Continue Reading

FridayJun 29, 2018 12:25 pm

CBDNewsBreaks – Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Actively Targets Cannabis Market in California

Vertically integrated cannabis company Sunniva’s (CSE: SNN) (OTCQX: SNNVF) core subsidiaries and licensed tenant cultivators are gearing up to supply the multibillion dollar recreational and medical cannabis industries in California. A recent article discussing the company’s unique technology reads: “Sunniva CEO Dr. Anthony Holler notes that the company has received all temporary state licenses required in California. Sunniva’s U.S. subsidiaries hold eight 10,000 square foot cultivation licenses, two manufacturing licenses, one 22,000 square foot cultivation license, one 22,000 square foot nursery license and one 10,000 square foot nursery license. Another seven 22,000 square foot cultivation bays will be leased to…

Continue Reading

FridayJun 29, 2018 9:54 am

CBDNewsBreaks – Earth Science Tech, Inc. (ETST) Adds Three New Products to Full Spectrum CBD Chocolate Line

Innovative biotech company Earth Science Tech (OTC: ETST) this morning announced that it is expanding its full spectrum cannabinoid (“CBD”) chocolate line with three unique new products formulated with the company’s joint venture partner, Karmavore Superfoods. The new products, Raw Dark Chocolate Covered Mangoes, Raw Dark Chocolate Coconut Peppermint Cups, and Raw Dark Chocolate Caramelized Quinoa Crunch, bring the company’s total to five unique CBD Raw Chocolate flavors. Production of the new products is currently underway and ETST anticipates a successful launching within the third quarter of 2018. “Our joint venture with Karmavore Superfoods has been a true blessing. Brian…

Continue Reading

FridayJun 29, 2018 9:33 am

CBDNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Adds Prem Virmani as Chair of Beverage Science and Research Division

Cannabis-focused research and development company The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) this morning announced that Prem Virmani, former senior vice president of global science and research for Cott Beverages, Inc., has been appointed Chair of TGOD’s Beverage Science and Research Division. Per the update, Virmani has over four decades of applicable industry experience, leading development in every major category, including the Sam’s Choice cola program for Walmart, the President’s Choice cola program for Loblaws and other major private label brands for Publix, Wegmans and Safeway. “I am delighted that Prem has joined the TGOD Leadership team,”…

Continue Reading

FridayJun 29, 2018 9:27 am

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application Following Breakthrough Discovery of Enhanced Drug Delivery to Brain Tissue

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. The company reached a breakthrough discovery during recent laboratory testing that demonstrated significantly enhanced drug delivery to brain tissue. Evidence from the study showed unexpected effectiveness in crossing the blood-brain barrier ("BBB") which Lexaria is investigating more extensively, leading to the company's…

Continue Reading

ThursdayJun 28, 2018 2:52 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Continues to Build Patent Portfolio

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is in the process of preparing new patent application filings and expects to receive more patent awards this year to add to its collection of over 40 patent awards or applications from 40 countries globally. A recent article discussing the company reads: “The total, once granted, would be four patents in the U.S. and four in Australia. All eight are for the family of “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” The development represents the first time that LXRP has expanded its patent protection outside of…

Continue Reading

ThursdayJun 28, 2018 11:48 am

CBDNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Innovative Therapies as Alternative Medicine Market Surges

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing pioneering options for preventive and curative therapies by utilizing several creative pathways. An article further discussing the company reads: “Chronic diseases and recurring health care issues are taking an increasingly bigger piece of the economic pie and disrupting the lives of many millions of people. U.S. health care costs for chronic diseases totaled $1.1 trillion in 2016 and balloon to $3.7 trillion when lost economic productivity is calculated into the total economic impact. According to a new report by Grand View Research, people around the world, along with their…

Continue Reading